Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Position reduced by Assenagon Asset Management SABy Publishing TeamJanuary 15, 2023 Assenagon Asset Management SA reduced its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 83.2% during…
Short-term stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) drops 11.9%By Publishing TeamJanuary 2, 2023 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) was the target of a significant decline in short interest in December. As…
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average “Moderate Buy” Recommendation From AnalystsBy Publishing TeamJanuary 1, 2023 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) received an average recommendation of “moderate buy” from the nine research…
